Role of arachidonic acid in the regulation of the NMDA-evoked release of acetylcholine in striatal compartments.
The role of endogenously released arachidonic acid in the control of the NMDA (50 microM)-evoked release of [3H]-acetylcholine previously formed from [3H]-choline was investigated in striosome-enriched areas and in the matrix of the rat striatum using a microsuperfusion procedure in vitro. Experiments were performed with either mepacrine (0.2 microM) or bovine serum albumin (BSA, 0.02%) which inhibits phospholipase A2 activity or binds endogenously released arachidonic acid, respectively. Both treatments similarly reduce the NMDA-evoked release of [3H]-acetylcholine, this effect being more pronounced in striosomes than in the matrix. These reductions result from a facilitation of dopamine release, since they were not observed in the presence of (-)sulpiride, the D2 dopamine receptor antagonist. Moreover, the superfusion with BSA was shown to enhance the release of [3H]-dopamine (formed from [3H]-tyrosine), this effect being of larger amplitude in striosomes than in the matrix. In control conditions, due to the blockade of the presynaptic inhibitory effect of GABA on dopamine release, bicuculline (GABA(A) receptor antagonist) reduces the NMDA-evoked release of [3H]-acetylcholine in both striatal compartments. Bicuculline was no longer effective following superfusions with either mepacrine or BSA, suggesting that these treatments eliminate the GABAergic presynaptic inhibitory control on dopamine transmission and thus lead to the dopamine-mediated inhibition of [3H]-acetylcholine release. These results indicate that arachidonic acid endogenously formed under weak stimulation of NMDA receptors contributes to the regulation of the evoked release of [3H]-acetylcholine by facilitating GABAergic transmission and that this process is more important in striosomes than in the matrix.